{"product_id":"roivant-business-model-canvas","title":"Roivant Sciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoivant Sciences: Business Model Unveiled\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic engine behind Roivant Sciences's innovative approach to drug development with our comprehensive Business Model Canvas. This detailed breakdown illuminates their unique value proposition, key partners, and revenue streams, offering a clear roadmap to their success.\u003c\/p\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Roivant Sciences's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances with Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences cultivates key partnerships with major pharmaceutical firms to advance its drug pipeline. These alliances often involve licensing agreements, co-development efforts, and shared commercialization responsibilities for Roivant's promising drug candidates.\u003c\/p\u003e\n\u003cp\u003eA prime example is Roivant's collaboration with Organon for VTAMA, a topical treatment for plaque psoriasis. This partnership structure typically includes substantial upfront payments and the potential for milestone payments, which not only validate Roivant's assets but also furnish crucial capital for ongoing research and development activities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborations with Academic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences actively partners with top universities and research centers to tap into groundbreaking science. These collaborations are essential for spotting new ways to treat diseases and identifying promising drug candidates, which directly fuels Roivant's development pipeline with innovative therapies.\u003c\/p\u003e\n\u003cp\u003eThese academic alliances are instrumental in Roivant's strategy to access early-stage discoveries. For instance, in 2024, Roivant continued to build upon its network of research collaborations, focusing on areas with high unmet medical needs, thereby accelerating the identification of novel therapeutic targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRelationships with Contract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences heavily leverages Contract Research Organizations (CROs) to manage its extensive preclinical and clinical research.  These partnerships are crucial for efficiently executing trials across Roivant's diverse portfolio of drug candidates.\u003c\/p\u003e\n\u003cp\u003eCROs offer specialized scientific expertise, state-of-the-art facilities, and dedicated personnel, which are vital for accelerating drug development timelines.  For instance, in 2024, Roivant's subsidiary, Axovant Sciences, announced a significant collaboration with a leading CRO to advance its gene therapy programs, highlighting the critical role these relationships play in operational execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestment Partners and Capital Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoivant Sciences cultivates crucial relationships with a broad spectrum of investment partners and capital providers. These include venture capitalists, private equity firms, and substantial mutual funds, all essential for fueling the high-cost drug development pipeline.\u003c\/p\u003e\n\u003cp\u003eThese partnerships are critical for securing the significant capital required for extensive clinical trials and research. For instance, in 2024, Immunovant, a Roivant subsidiary, successfully completed a private placement, raising substantial funds to extend its financial runway and advance its ongoing programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eVenture Capitalists:\u003c\/strong\u003e Provide early-stage funding and strategic guidance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePrivate Equity Firms:\u003c\/strong\u003e Offer later-stage growth capital and operational expertise.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMutual Funds:\u003c\/strong\u003e Contribute significant, long-term investment capital.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Investors:\u003c\/strong\u003e Offer industry-specific knowledge and potential commercial collaborations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Platform Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoivant Sciences actively pursues technology and platform collaborations to bolster its drug development capabilities. These partnerships are vital for integrating cutting-edge advancements into their pipeline, enabling the creation of more effective and targeted therapies.\u003c\/p\u003e\n\u003cp\u003eBy teaming up with specialists in areas like lipid nanoparticle (LNP) and ligand conjugate technologies, Roivant enhances its capacity for next-generation therapeutics. For instance, collaborations in LNP technology are critical for delivering mRNA-based treatments, a rapidly growing area in biopharmaceuticals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Alliances for Innovation:\u003c\/strong\u003e Roivant's partnerships focus on acquiring or co-developing advanced drug delivery platforms, such as those utilizing lipid nanoparticles and ligand conjugates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhancing Therapeutic Potential:\u003c\/strong\u003e These collaborations are instrumental in improving the efficacy, safety, and targeting capabilities of Roivant's drug candidates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e By leveraging these cutting-edge technologies, Roivant strengthens its long-term value proposition and maintains a competitive edge in the biopharmaceutical landscape.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Propel Pharmaceutical Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences strategically partners with major pharmaceutical companies, exemplified by its 2024 collaboration with Organon for VTAMA. These alliances often involve licensing and co-development, providing upfront payments and milestone potential to fuel R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eAcademic institutions are crucial for identifying early-stage discoveries, with Roivant actively expanding its research collaborations in 2024 to target high unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eRoivant relies heavily on Contract Research Organizations (CROs) to efficiently manage its diverse drug development pipeline, as seen with Axovant Sciences' 2024 collaboration with a leading CRO for gene therapy programs.\u003c\/p\u003e\n\u003cp\u003eAccess to capital is secured through partnerships with venture capitalists, private equity, and mutual funds, critical for funding extensive clinical trials. For instance, Immunovant's 2024 private placement highlights this need.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eExample\/2024 Activity\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMajor Pharma\u003c\/td\u003e\n\u003ctd\u003eCo-development, Licensing\u003c\/td\u003e\n\u003ctd\u003eOrganon (VTAMA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniversities\/Research Centers\u003c\/td\u003e\n\u003ctd\u003eEarly-stage discovery access\u003c\/td\u003e\n\u003ctd\u003eExpanding collaborations for novel targets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eClinical trial execution\u003c\/td\u003e\n\u003ctd\u003eAxovant Sciences' gene therapy program support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital Providers\u003c\/td\u003e\n\u003ctd\u003eFunding R\u0026amp;D and trials\u003c\/td\u003e\n\u003ctd\u003eImmunovant's 2024 private placement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA dynamic, data-driven business model focusing on identifying and advancing underperforming drug assets through specialized subsidiary companies.\u003c\/p\u003e\n\u003cp\u003eThis model leverages a de-risking approach by partnering with established pharmaceutical companies and focusing on specific therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eRoivant Sciences' Business Model Canvas acts as a pain point reliever by offering a high-level view of their drug development strategy with editable cells, allowing for rapid adaptation and efficient problem-solving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences' core activity is the discovery, preclinical, and clinical development of new medicines. This means they take promising drug candidates from early-stage research all the way through rigorous testing in humans to prove they are safe and effective for patients.\u003c\/p\u003e\n\u003cp\u003eThis process involves identifying potential new therapies for a range of diseases and then meticulously guiding them through multiple phases of clinical trials. For example, in 2024, Roivant continued to advance its pipeline, with several of its subsidiaries focusing on specific therapeutic areas, demonstrating the breadth of their R\u0026amp;D efforts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormation and Management of 'Vant' Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences' core activity revolves around creating and managing its portfolio of subsidiary companies, branded as 'Vants.' This unique structure allows for the focused development of specific therapeutic areas or innovative drug technologies.\u003c\/p\u003e\n\u003cp\u003eThis decentralized approach, exemplified by Vants like Axovant (gene therapy) and Dermavant (dermatology), fosters agility and specialized expertise, crucial for navigating the complex drug development landscape. For instance, in 2024, Roivant continued to advance its Vant pipeline, with several candidates progressing through clinical trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution and Data Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences actively manages and executes a broad array of clinical trials, a core activity for generating high-quality data essential for regulatory submissions.  This involves overseeing numerous studies across its various operating companies, or 'Vants'.\u003c\/p\u003e\n\u003cp\u003eFor instance, Roivant's Vant, Dermavant, conducted pivotal trials for brepocitinib in dermatomyositis, aiming to demonstrate efficacy and safety. Similarly, Immunovant, another Vant, is progressing with IMVT-1402 trials for Graves' disease, a key step in gathering the necessary evidence for potential market approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Submissions and Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePreparing and submitting detailed regulatory applications to health authorities, such as the U.S. Food and Drug Administration (FDA), is a core activity for Roivant Sciences. This involves meticulously compiling data from clinical trials and manufacturing processes to demonstrate the safety and efficacy of their drug candidates.\u003c\/p\u003e\n\u003cp\u003eNavigating the complex and often lengthy approval process is critical. Roivant's success in achieving regulatory milestones directly impacts their ability to commercialize new therapies. For instance, the FDA approval of VTAMA (tapinarof) cream for plaque psoriasis in 2022 was a significant achievement, paving the way for revenue generation.\u003c\/p\u003e\n\u003cp\u003eKey aspects of this activity include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDossier Preparation:\u003c\/strong\u003e Compiling extensive documentation, including preclinical data, clinical trial results, manufacturing information, and proposed labeling, for submission to regulatory bodies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSubmission Management:\u003c\/strong\u003e Electronically submitting applications and responding to queries from health authorities throughout the review process.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-Approval Compliance:\u003c\/strong\u003e Ensuring ongoing adherence to regulatory requirements after a drug is approved, including pharmacovigilance and manufacturing standards.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio Strategy and Asset Monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoivant Sciences actively manages its extensive pipeline, making crucial decisions about advancing specific assets and seeking ways to generate value. This includes exploring avenues like licensing agreements or creating independent spin-off companies.\u003c\/p\u003e\n\u003cp\u003eA prime example of this strategy in action is the significant $7 billion deal Roivant inked with Roche for its subsidiary, Telavant. This transaction highlights Roivant's capability in successfully monetizing its assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Pipeline Evaluation:\u003c\/strong\u003e Roivant continuously assesses its portfolio of drug candidates to prioritize development and resource allocation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMonetization Initiatives:\u003c\/strong\u003e The company actively pursues licensing deals, partnerships, and spin-offs to unlock the value of its assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue Maximization:\u003c\/strong\u003e These activities are designed to maximize shareholder value through strategic divestitures and collaborations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecent Success:\u003c\/strong\u003e The $7 billion sale of Telavant to Roche in late 2023 exemplifies Roivant's effective asset monetization strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoivant's Strategic Biopharma Development and Asset Value Creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences' key activities center on the strategic management and development of its biopharmaceutical pipeline through its decentralized subsidiary model, the Vants. This involves identifying promising drug candidates, advancing them through rigorous clinical trials, and navigating the complex regulatory approval process. For example, in 2024, Roivant continued to progress multiple Vants, with several drug candidates in various stages of clinical development, underscoring their active R\u0026amp;D efforts.\u003c\/p\u003e\n\u003cp\u003eA significant aspect of their operations is the execution of clinical trials, generating critical data for regulatory submissions. Dermavant's trials for brepocitinib in dermatomyositis and Immunovant's progress with IMVT-1402 for Graves' disease in 2024 highlight this focus. Roivant also actively manages its portfolio by seeking monetization opportunities, such as the $7 billion deal with Roche for Telavant in late 2023, demonstrating their ability to realize value from their assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024 Focus\/Example\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Development \u0026amp; Management\u003c\/td\u003e\n\u003ctd\u003eDiscovering, developing, and managing a portfolio of drug candidates via specialized Vants.\u003c\/td\u003e\n\u003ctd\u003eAdvancing multiple Vants through clinical trials; strategic pipeline evaluation and prioritization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Execution\u003c\/td\u003e\n\u003ctd\u003eConducting rigorous clinical trials to demonstrate safety and efficacy of drug candidates.\u003c\/td\u003e\n\u003ctd\u003eDermavant's brepocitinib trials; Immunovant's IMVT-1402 trials for Graves' disease.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003ePreparing and submitting comprehensive dossiers to health authorities for drug approval.\u003c\/td\u003e\n\u003ctd\u003eOngoing submissions and responses to regulatory bodies for pipeline assets.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Monetization\u003c\/td\u003e\n\u003ctd\u003eSeeking partnerships, licensing agreements, and divestitures to realize asset value.\u003c\/td\u003e\n\u003ctd\u003eTelavant sale to Roche for $7 billion (late 2023) as a precedent for value creation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas you are previewing is the exact document you will receive upon purchase. This is not a sample or mockup, but a direct representation of the comprehensive analysis you will gain access to. Once your order is complete, you will download this identical file, ready for immediate use and application to your strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55538323227001,"sku":"roivant-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/roivant-business-model-canvas.png?v=1753618716","url":"https:\/\/portersfiveforce.com\/products\/roivant-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}